secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0001558370-24-016372
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio completes $25M Gilead investment; XTX301 shows no DLTs in Phase 1; cash into Q3 2025
--------------------------------------------------------------------------------

- Completed $8.2M Gilead private placement (common + prefunded warrants), exhausting $25M stock purchase agreement.
- Preliminary Phase 1 data for XTX301 (IL-12) in 34 patients: no DLTs, no Grade 4/5 AEs, sustained IFN-gamma signaling.
- No measurable activated XTX301 in peripheral circulation; majority of AEs Grade 1/2 (flu-like, CRS, transaminitis).
- Cash runway guidance updated: existing cash + equivalents expected to fund operations into Q3 2025.
- Initial Phase 2 data for vilastobart (XTX101) + atezolizumab in MSS CRC to be presented at ASCO GI (Jan 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024016372/0001558370-24-016372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024016372/xlo-20241218x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer